Manlius Pebble Hill students dive into AI innovation
Manlius, N.Y. (WSYR-TV) – Students at Manlius Pebble Hill School are getting a head start in a subject most high schoolers don't even touch: artificial intelligence. For senior Andy Wladis, the opportunity to dive into AI was too good to pass up.
'I emailed my guidance counselor. I emailed the head of the school and said, 'I have a huge passion for this. I would love to take these classes,'' Wladis said. 'It was one of the best decisions I've made at MPH.'
Dr. Gus Lott teaches the AI elective. He says the class is about exploration as much as instruction. He encourages students to experiment with AI tools in a hands-on environment unique from other schools in Upstate New York.
'Other teachers, reasonably, say, 'Don't use AI in this class—we want you to do the work,'' Lott explained. 'But in my class, it's like, 'Use AI. What's it like to use a speech writer to do the writing for you?'
It's not about cutting corners, it's about understanding the tool and using it responsibly. Students are expected to be transparent when using AI, and many teachers at MPH support that approach.
'If you want to use it to outline, that's completely fine,' Wladis said. 'You just have to tell them that you're using it so it's very clear. Our teachers are open to innovation.'
Dr. Lott compares AI to a modern research assistant or Google Scholar, saying it provides students with a lot of information; he said, 'It's kind of a new version of a Google Scholar search, or a librarian, or a research assistant.'
For students like Wladis, the course isn't just an elective—it's a launchpad. He's heading to Arizona State University in the fall to study computer science, and says MPH played a key role in preparing him.
'I think MPH has really helped me develop my skill set, both academically and socially,' he said. 'I'm really thankful for MPH, and I'm really thankful for the future.'
With AI continuing to shape the world, these students aren't just learning how to use it—they're getting ready to lead the way.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Datasite Acquires Leading Private Market Intelligence Company Grata with $500 Million Investment Commitment
MINNEAPOLIS--(BUSINESS WIRE)-- Datasite, the global SaaS provider of AI-powered workflow collaboration and automation solutions for M&A, investment and strategic projects, today announced that it has acquired Grata, a leading AI-native, private market intelligence company. CapVest Partners LLP ('CapVest'), the controlling shareholder of Datasite, intends to invest $500 million, organically and inorganically, to further expand Datasite's intelligence solutions. "Grata has comprehensive, accurate, and searchable data on private companies. Combine that with the Datasite Group's anonymized and aggregated insights, and you've got an unmatched powerhouse of market intelligence.' 'This landmark combination creates a unique market intelligence offering for enterprises globally,' said Rusty Wiley, CEO and President of Datasite. 'Grata has comprehensive, accurate and searchable data on private companies. Combine that with the Datasite Group's anonymized and aggregated insights – from the largest and most trusted database in the world, capturing over 55,000 projects every year – and you've got an unmatched powerhouse of market intelligence.' Founded in 2016, New York-based Grata offers an AI-native platform for private market workflows combining proprietary company data with integrated dealmaking software solutions. Datasite's acquisition and ongoing investment in Grata will accelerate the growth of its pioneering, deal sourcing and market intelligence tools. Co-founders Andrew Bocskocsky and Nevin Raj will continue to lead Grata as a strategic business unit within Datasite. 'We are thrilled to join the Datasite team and back our shared vision with significant investment,' said Andrew Bocskocsky, CEO and Co-Founder of Grata. 'Together, with Datasite's global footprint, we are expanding our reach to international markets and creating unprecedented value for users.' Christopher Campbell, Partner at CapVest, said, 'Obtaining accurate, real-time data on private markets will further enable enterprises and investors to execute their strategic priorities. We welcome Grata to the Datasite Group and look forward to bringing unique insights to the M&A community.' Datasite was advised by Arma Partners (M&A), Willkie Farr & Gallagher LLP (Legal), Alvarez & Marsal (Financial), KPMG (Tax), Lockton (Insurance) and West Monroe (Technology). Grata was advised by Deutsche Bank (M&A) and Orrick (Legal). To learn more about Datasite, please visit: About Datasite Datasite is a global SaaS provider of AI-powered workflow collaboration and automation solutions for M&A, investment and strategic projects. Datasite's innovative products drive execution, while generating unique data insights to empower knowledge workers around the world to succeed across the entire project lifecycle. For more information, visit About Grata Grata is a leading AI-native private market intelligence and dealmaking company. Grata has the most comprehensive, accurate, and searchable data on private companies. For more information, visit
Associated Press
an hour ago
- Associated Press
Quantivision Business Institute (QBI) Announces Collaboration with Major Exchanges for Global Launch of MindArc 5.0 on September 1, 2025
San Diego, USA, June 03, 2025 (GLOBE NEWSWIRE) -- On May 31, 2025, Quantivision Business Institute (QBI) officially announced that its flagship intelligent trading system, MindArc 5.0, will be launched simultaneously on major global exchanges on September 1, 2025. Through global cloud deployment, it will provide high-performance and secure intelligent trading support to investors worldwide. Leading a New Era of Secure Intelligent Trading Founded in 2015 by fintech pioneer Professor Marcus J. Hayes, QBI is dedicated to combining cutting-edge AI technology, security compliance systems, and education to provide reliable fintech solutions for global investors and professionals. Over the years, QBI has become a leader in fintech education and innovative trading systems. MindArc 5.0 is QBI's self-developed intelligent trading analysis system, which has undergone years of technological iteration since its initiation in 2019. The system covers stock, cryptocurrency, forex, and commodities markets, featuring comprehensive risk control capabilities and intelligent analysis models, making it particularly suitable for high-frequency trading and quantitative investment. Industry-Leading Security Protections MindArc 5.0 includes several core security features to ensure the safety of user funds and data: The system also features self-optimization capabilities, continuously learning from user behavior and market data to enhance strategy precision, providing users with more efficient and personalized investment decision support. Comprehensive Global Launch Plan QBI is currently collaborating with multiple major exchanges in North America, Asia, and Europe. MindArc 5.0 will gradually launch starting in September 2025, leveraging global cloud services to provide investors with a seamless access experience. This deployment will significantly enhance the system's coverage and user experience, further solidifying QBI's leading position in intelligent trading and secure finance. Leading Experts Set to Establish Industry Standards QBI boasts a world-class faculty and technical team: Both experts designed the security and compliance architecture of MindArc 5.0 and incorporated practical case studies into QBI's educational curriculum to help users systematically master AI risk control and trading strategies. Balancing Education and Technology, Expanding Global Influence QBI has trained over 100,000 fintech professionals, with alumni at renowned institutions like Two Sigma, Bridgewater Associates, and Renaissance Technologies, and established strategic partnerships with Harvard and Stanford. QBI also promotes global financial literacy through an education fund, aiming to provide equitable educational resources to aspiring fintech individuals. Towards an Intelligent and Secure Financial Future QBI remains committed to the philosophy of 'technology for good, security as the foundation,' achieving efficient integration of technology and market through MindArc 5.0. This global launch is not only a demonstration of system capabilities but also an important milestone in QBI's commitment to promoting intelligent finance worldwide. Whether you are a professional trader or an emerging investor, QBI will be your trusted partner. Media Contact Company Name: Quantivision Business Institute (QBI) Contact: Neill Aldridge Website: Email: [email protected] Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Neill Aldridge Service(at)
CNET
an hour ago
- CNET
The FDA Warns of New Zyrtec and Xyzal Side Effect. What Is Pruritus?
According to the FDA, 62.7 million over-the-counter packages of Zyrtec (cetirizine) and Xyzal (levocetirizine) were purchased in 2022. Since allergies are getting worse -- partly because of climate change creating longer, more intense pollen seasons -- these numbers have likely climbed in the last three years as more people purchase the antihistamines to cope with allergy symptoms like a stuffy nose, watery, red, itchy eyes and hives. For the millions of people who take these drugs, it's important to know that the FDA recently published a warning about a newly discovered side effect that may occur after taking both Zyrtec and Xyzal. If you stop taking Zyrtec or Xyzal after long-term use, you might experience "rare but severe" itching. Also called pruritus, this itching was experienced by patients who had been taking these allergy medicines every day for several months or years and then stopped. What is the FDA going to do? The FDA decided to issue this warning after identifying 209 cases worldwide -- 180 cases for cetirizine, 27 for levocetirizine and two for both -- of this particular side effect reported between April 2017 and July 2023. In the US, 197 cases were reported. However, there may be more, because these are only those that were reported to the FDA. Interestingly, even though most patients who experienced this severe itching had been taking these antihistamines for more than three months, some had this reaction after less than one month of use. Because of these findings, the FDA will now include a warning on the prescribing information for prescription cetirizine and levocetirizine. The administration is also asking that manufacturers add this warning to drug facts labels for OTC versions. When to contact your doctor If you stop taking OTC cetirizine or levocetirizine and develop severe itching within a few days after you've been using the medicine daily for several months to years, you should contact your doctor. If you plan to take these medicines for a prolonged period of time, you should also discuss the pros and cons with your doctor before starting. How to treat this new Zyrtec and Xyzal side effect According to the FDA, no effective treatments for pruritus have been found. However, most patients discovered that their symptoms resolved after they restarted cetirizine or levocetirizine or after they tapered off the antihistamine after restarting it. Before you try this, consult your doctor to make sure that's the best course of action if you think you're dealing with this Zyrtec or Xyzal complication. According to the FDA, the most common, already-known side effects of cetirizine and levocetirizine are fatigue, drowsiness, sore throat, cough, dry mouth, nosebleed, fever, diarrhea and vomiting. What is pruritus? Plus, additional symptoms to know The Cleveland Clinic reports that pruritus is the medical term for "itchiness." It can be painful or irritating and spread to multiple areas of the body. Other symptoms of pruritus can include a rash, blisters, large bumps, small pimple-like bumps and skin discoloration. Scratching the skin can cause additional symptoms, such as skin breaks and bleeds, scratch marks, dry or cracked skin, broken skin that leaks a yellow to white fluid (infection), localized pain where the skin itches and a thick, leathery patch. That is why it's important to do what you can to manage your itching under the care of a doctor. Dry skin, pregnancy, contact with an allergen and a reaction medication are common causes of pruritus. If it occurs for over six weeks, it can be considered chronic.
